---
title: "Pomdoctor Posts Strong 2025 Revenue Growth but Wider Loss as IPO and R&D Spending Climb"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286472794.md"
description: "PomDoctor Ltd. reported a 16.7% increase in fiscal 2025 revenues to RMB399.9 million, driven by a 69.3% rise in Internet hospital revenue. However, the company faced a wider net loss of RMB130.9 million due to increased spending on sales, administration, and R&D, including IPO costs. R&D investment surged by 328.5%, focusing on AI and healthcare. Despite the revenue growth, Spark's AI Analyst rates POM as Neutral due to weak financial fundamentals and bearish technical momentum. PomDoctor operates an Internet hospital platform in China, specializing in chronic disease management."
datetime: "2026-05-14T21:37:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286472794.md)
  - [en](https://longbridge.com/en/news/286472794.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286472794.md)
---

# Pomdoctor Posts Strong 2025 Revenue Growth but Wider Loss as IPO and R&D Spending Climb

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

PomDoctor Ltd. Unsponsored ADR ( (POM) ) has shared an update.

Pomdoctor Limited reported its fiscal 2025 results on May 14, 2026, showing net revenues rising 16.7% to RMB399.9 million, driven by a 69.3% surge in Internet hospital revenue as online pharmacy sales nearly doubled. However, gross margin narrowed to 13.1% and net loss widened to RMB130.9 million due to sharply higher sales, administrative and R&D spending, including significant non-recurring IPO and investor relations costs.

Management highlighted a 328.5% jump in R&D investment, particularly in AI and healthcare applications, and said the IPO has strengthened its ability to access capital for expansion. The company plans to deepen partnerships with pharmaceutical manufacturers, integrate further with online medical insurance systems, and pursue an “AI + medical-grade smart wearables + full-cycle chronic disease management” strategy to reinforce its position in China’s competitive digital healthcare market.

**Spark’s Take on POM Stock**

According to Spark, TipRanks’ AI Analyst, POM is a Neutral.

The score is driven primarily by weak financial fundamentals (persistent losses and negative equity) and bearish technical momentum (negative MACD, price below key moving averages). Valuation impact is limited because P/E and dividend data were not provided.

To see Spark’s full report on POM stock, click here.

**More about PomDoctor Ltd. Unsponsored ADR**

Pomdoctor Limited is a Guangzhou-based provider of online medical services focused on chronic disease management in China. Listed on Nasdaq, the company operates an Internet hospital platform with online consultations and pharmacy sales, alongside a pharmaceutical supply chain business serving wholesale and retail pharmacy customers.

**Average Trading Volume:** 7,146,816

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $16.21M

For an in-depth examination of POM stock, go to TipRanks’ Overview page.

### Related Stocks

- [POM.US](https://longbridge.com/en/quote/POM.US.md)

## Related News & Research

- [POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results | POM Stock News](https://longbridge.com/en/news/286463818.md)
- [Gen Z's AI backlash is getting louder](https://longbridge.com/en/news/286922566.md)
- [Jim Cramer Says Nvidia Should Stay Inside China’s AI Boom, Not Walk Away](https://longbridge.com/en/news/286804523.md)
- [Google's latest AI flex came with Silicon Valley's new favorite word](https://longbridge.com/en/news/286951990.md)
- [Water Quality Reports Available Online for New Jersey American Water Customers | AWK Stock News](https://longbridge.com/en/news/286463075.md)